Steven K. Libutti, MD, FACS

Steven K. Libutti, MD, FACS

Director, Rutgers Cancer Institute of New Jersey

Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences

Senior Vice President, Oncology Services, RWJBarnabas Health

Professor of Surgery, Rutgers Robert Wood Johnson Medical School

 

Biography

Steven K. Libutti, MD, FACS, was appointed as Director of Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. In addition to his leadership roles within Rutgers University, Dr. Libutti also serves as Senior Vice President of Oncology Services for RWJBarnabas Health, further strengthening the university’s partnership with the healthcare system. He is also a Professor of Surgery at Rutgers Robert Wood Johnson Medical School.

Most recently, Dr. Libutti served as Director for the Montefiore Einstein Center for Cancer Care in New York City and was a Professor and Vice Chairman of the Department of Surgery and Professor in the Department of Genetics at Albert Einstein College of Medicine and Montefiore Health System. A surgical oncologist, Dr. Libutti is an internationally known expert in endocrine surgery and the management of neuroendocrine tumors. He is the immediate Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas.

The recipient of funding from the National Cancer Institute (NCI) for the past 20 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment and blood vessel formation in tumors. He is studying tumor neovascular formation and the interaction between tumor cells, endothelial cells and the components of the tumor microenvironment including fibroblasts and cancer stem cells. His work also focuses on a better understanding of the tumor suppressor genes MEN1 and FILIP1L.

After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the NCI in surgical oncology and endocrine surgery. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch.  He has published over 280 peer reviewed journal articles, is Editor-in-Chief of the Nature Journal Cancer Gene Therapy, and holds seven U.S. patents. 

Dr. Libutti Discusses Advances in Cancer Research and Patient Care on NJTV 

Education and Training

    Post-Graduate Education

    • Fellow in Surgical Oncology, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 1995-96.
    • Chief Resident in Surgery, Presbyterian Hospital, New York, NY 1994-95
    • Resident in Surgery, Presbyterian Hospital, New York, NY 1991-94
    • Intern in Surgery, Presbyterian Hospital, New York, NY 1990-91

    Medical and Undergraduate Education

    • College of Physicians & Surgeons of Columbia University, New York, NY 
      Doctor of Medicine, May 1990
    • Harvard College, Harvard University, Cambridge, MA
      Bachelor of Arts in Biology, magna cum laude, June 1986

    Academic Appointments

    • Director, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ 2017 - Present
    • Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ 2017 - Present
    • Professor (Tenured), Department of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 2017 - Present
    • Professor (Tenured), Departments of Surgery and Genetics, Albert Einstein College of Medicine, Bronx, NY 2009-2017
    • Vice Chairman, Department of Surgery, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 2009-2017
    • The Marvin L. Gliedman, M.D., Distinguished Surgeon, Montefiore Medical Center, Bronx, NY 2009-2017
    • Director, Montefiore-Einstein Center for Cancer Care, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY 2009-2017
    • Associate Director, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 2009-2017
    • Director, Endocrine Tumor Program, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 2013-2017
    • Professor of Surgery, Uniformed Services University of the Health Sciences, F. Edward Hébert School of Medicine, Bethesda, MD 2007-Present
    • Head, Tumor Angiogenesis Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 2006-2009
    • Senior Investigator (Tenured), Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 2006-2009
    • Investigator (Tenure Track), Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 2001-2006
    • Staff Clinician, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 2000-2001 
    • Senior Clinical Investigator (Commissioned Corps), Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 1999-2000
    • Clinical Investigator (Commissioned Corps), Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 1996-1999
    • Assistant Professor of Surgery, Uniformed Services University of the Health Sciences, F. Edward Hébert School of Medicine, Bethesda, MD 1996-2007
    • Clinical Associate (Commissioned Corps), Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 1995-1996
    • Administrative Chief Resident, Department of Surgery, College of Physicians & Surgeons, Columbia University, New York, NY 1994-95
    • Post-Doctoral Residency Fellow, Department of Surgery, College of Physicians & Surgeons, Columbia University, New York, NY 1990-95

    Hospital Staff Appointments

    • Senior Vice President, Oncology Services, RWJBarnabas Health, New Brunswick, NJ 2017 - Present
    • Member, Robert Wood Johnson University Hospital Board of Trustees, New Brunswick, NJ 2017 - Present
    • Trustee, Rutgers Health Group, Inc. Board of Trustees, New Brunswick, NJ 2017 - Present
    • Vice Chairman, Department of Surgery, Montefiore Medical Center, Bronx, NY 2009-2017
    • Director of Surgery, Jack D. Weiler Hospital, Montefiore Medical Center, Bronx, NY 2009-2017
    • Attending Surgeon, Walter Reed Army Medical Center, Washington, DC 2007-2010
    • Senior Staff Attending Surgeon, Clinical Center, National Institutes of Health, Bethesda, MD, 1996-2009
    • Junior Staff Fellow, Clinical Center, National Institutes of Health, Bethesda, MD, 1995-1996
       

    Society Memberships, Advisory Boards and Committees

    • Fellow of the American College of Surgeons
    • Fellow of the Society of Surgical Oncology
    • American Association of Endocrine Surgeons, Past President
    • International Association of Endocrine Surgeons
    • Fellow of the American Surgical Association
    • American Joint Committee on Cancer, Member
    • American College of Surgeons’ Commission on Cancer (NCI and SEER Representative)
    • Society of University Surgeons
    • Society of Surgical Oncology, Chair, Technology and Communications Committee
    • Society of Clinical Surgery
    • Alliance for Clinical Trials in Oncology, Board of Directors
    • Eastern Cooperative Oncology Group
    • The Endocrine Society
    • John Jones Surgical Society, President 2010-2013, Past President 2013-
    • Association for Academic Surgery
    • American Association for Cancer Research
    • American Society of Clinical Oncology
    • The Neuroendocrine Tumor Alliance, Scientific Advisory Board (Charter Member)
    • Association of Military Surgeons of the United States
    • Institutional Review Board, National Cancer Institute, Chairman
    • National Cancer Institute Representative, NIH Human Subjects Research Advisory Committee
    • National Cancer Institute Tumor Angiogenesis and Invasion Working Group, Co-Chairman
    • Trans-Institute Angiogenesis Research Program, Executive Committee, Chair
    • NIH Assembly of Scientists, elected to Executive Council
    • NCI CCR Advisory Board
       

    Current Research Support

    3P30CA072720-19S4  Libutti (PI)  03/01/97-02/28/18
    Cancer Center Support Grant (CCSG)
    To conduct innovative basic, clinical and population research that: Expands our understanding of the etiology and biology of cancer; facilitates the rapid translation of laboratory-based discoveries into human studies; develops new approaches and interventions for cancer prevention that decrease cancer incidence and mortality; and develops new and better therapies to decrease suffering and mortality from cancer
    Total Support: $2,651,316

    3P30CA072720-19S5  Libutti (PI)  09/01/15-02/28/18
    Cancer Center Support Grant Supplement
    Community Health Educators (CHEs)
    Total Support: $125,000

    R01CA170911  Libutti (PI)  09/01/12-06/30/17
    “Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis”
    NCI Provocative Questions RFA
    Total Support: $1,732,625

    DOD W81XWH-15-1-0369  Libutti (PI)  09/01/15-08/31/18
    “FILIP1L inhibits ovarian cancer metastasis through inhibition of WNT signaling”
    Total Support: $757,477

    P50CA174521  Libutti (PI)  09/01/16-08/31/17
    Pilot Grant from University of Iowa NET SPORE
    “Development of a Novel Immune-Checkpoint Inhibitor: B7x Blockade in Neuroendocrine Tumors (NETs)”
    Total Support: $50,000

    Completed Research Support

    4P30CA072720-19   Libutti (PI)   09/01/15-02/28/18
    Cancer Center Support Grant (CCSG)
    Supports programs and core resources for the NCI-designated Comprehensive Cancer Center
    Total Support: $2,415,701

    T32CA200561  Libutti (PI)  12/01/15-11/30/20
    “Training of Surgeons for Studies of the Tumor Microenvironment”
    Total Requested Support: $1,352,720

    R01DK079970  Levine (Libutti Sub-K)  09/22/12-06/30/16
    “The role of GCM2 in parathyroid gland homeostasis”
    Total Support: $235,524

    P50CA174521  Libutti (PI)  09/01/15-08/31/16
    Pilot Grant from University of Iowa NET SPORE
    Characterization of new B7 immune-checkpoints in the tumor microenvironment of human carcinoid and pancreatic neuroendocrine tumors.
    Total Support: $50,000

    U54CA151668 8847  Libutti (PI)  09/01/10-08/31/16
    “Multifunctional Nanoassemblies for Ligand-Directed Imaging and Therapy of Endocrine Tumors of the Pancreas”
    Total Support: $710,370

    Linda and Earle Altman  Libutti (PI)  06/01/10-06/30/15
    “Studies of the tumor microenvironment and tumor associated vasculature”
    Unrestricted research gift
    Total Support: $1,250,000

    2012 Caring for Carcinoid Foundation-AACR Grant for Carcinoid Tumor and Pancreatic  Neuroendocrine Tumor Research  Pasqualini (Libutti Co-PI)  07/01/12-06/30/14
    “Octreotide-targeted treatment of neuroendocrine tumors of the pancreas”
    Total Support: $250,000

    Speracura, LLC  Libutti (PI)  09/20/10-09/19/13
    Endocrine/Neuroendocrine Tumor Program 
    Total Support: $330,000

    Pheo/Para Alliance  Libutti (PI)  07/01/11-07/01/13
    “Genomic profiling of pheochromocytomas”
    Total Support: $75,000

    AECC - Pilot Project Grant  Libutti (PI)  03/01/11-02/28/12
    “To discover novel pathways involved in the formation of endocrine tumors using high throughput genomic approaches”
    Total Support: $15,000

    AECOM – Dean’s Pilot Grant  Libutti (PI)  06/01/11-05/31/12
    “Understanding the formation of endocrine tumors using high throughput global RNA massively-parallel sequencing”
    Total Support: $15,000

    NCI - Z01 SC 010368  Libutti (PI)  10/01/01-06/30/09                
    “Targeting the Tumor Vasculature to Treat Cancer”
    NCI Tenured Intramural Scientist: novel approaches to the targeted therapy of cancer.
    Total Support: $7,200,000

    Alliance  Libutti (Site PI)
    American College of Surgeons Oncology Group, cooperative clinical trials in cancer.  Sponsored by the National Cancer Institute. 
     

    Patents

    Bass LS, Libutti SK, Eaton AM, Tissue bonding and sealing composition and methods of using the same, U. S. Patents 5,209,776 and 5,292,362.

    Stern D, Clauss M, Kao J, Kayton ML, Libutti SK, Antibody which specifically binds to endothelial monocyte activating polypeptide II, U.S. Patent 5,641,867.

    Stern D, Clauss M, Kao J, Kayton ML, Libutti SK, Endothelial monocyte activating polypeptide II: a mediator which activates host response, U.S. Patents 6,228,837 and 6,734,168.

    Libutti SK, Zeiger MA, Mazzanti C, Umbricht C, Diagnostic tool for diagnosing benign versus malignant thyroid lesions, U.S. Patent 7,901,881.

    Libutti SK, Kwon M, Tandle A, FILIPIL compositions and methods for treating cancer, U.S. Patent 8,501,912.

    Libutti SK, He M, Molecular-based method of cancer diagnosis and prognosis, U.S. Patents 8,715,928, and 9,181,589.

    Libutti SK, Yuan Z, Combination therapy using a targeted inducer of apoptosis combined with an inhibitor of inhibitor of apoptotic proteins (IAP’s) for the treatment of cancer, U.S. Patent Pending, U.S. Serial No. 61/537,250.

    Selected Publications

    2014 - 2017   |   2012 - 2013   |   2010 - 2011

    2014 - 2017 Publications

    Chandra D, Selvanesan BC, Yuan Z, Libutti SK, Koba W, Beck A, Zhu K, Casadevall A, Dadachova E, Gravekamp C. 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. Oncotarget. 2017 Feb 6. doi: 10.18632/oncotarget.15117. [Epub ahead of print]. PMID: 28186976

    Libutti SK. Of mice and men(in) and what I have learned from both. Surgery. 2017 Jan;161(1):1-11. doi: 10.1016/j.surg.2016.10.004. PubMed PMID: 27865595

    Libutti SK. Editorial: Treatment  decision making in the era of genetic testing and molecular diagnostics. Surgery. 2017 Jan;161(1):228-229. doi: 10.1016/j.surg.2016. 10.009. PubMed PMID: 27863788

    Kwon M, Kim JH, Rybak Y, Luna A, Hun Choi C, Chung JY, Hewitt SM, Adem A, Tubridy E, Lin J, Libutti SK. Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer. Oncotarget. 2016 Oct 20. doi: 10.18632/oncotarget.12784. [Epub ahead of print] PubMed PMID: 27776341.

    Serrano OK, Love C, Goldman I, Huang K, Ng N, Abraham T, Da Silva R, Friedmann P, Libutti SK, Kennedy TJ. The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review. J Surg Oncol. 2016 May;113(6):640-6. doi: 10.1002/jso.24190. PubMed PMID: 27115836.

    Keutgen XM, Hammel P, Choyke PL, Libutti SK, Jonasch E, Kebebew E. Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau diseaseNat Rev Clin Oncol. 2016 Mar 31. doi: 10.1038/nrclinonc.2016.37. [Epub ahead of print] Review. PubMed PMID: 27030075.

    Smith TL, Yuan Z, Cardó-Vila M, Sanchez Claros C, Adem A, Cui MH, Branch CA, Gelovani JG, Libutti SK, Sidman RL, Pasqualini R, Arap W. AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas. Proc Natl Acad Sci U S A. 2016 Feb 16. pii: 201525709. [Epub ahead of print] PubMed PMID: 26884209.

    Yuan Z, Claros CS, Suzuki M, Maggi EC, Kaner JD, Kinstlinger N, Gorecka J, Quinn TJ, Geha R, Corn A, Pastoriza J, Jing Q, Adem A, Wu H, Alemu G, Du YC, Zheng D, Greally JM, Libutti SK. Loss of MEN1 activates DNMT1 implicating DNA hypermethylation as a driver of MEN1 tumorigenesis. Oncotarget. 2016 Feb 9. doi: 10.18632/oncotarget.7279. [Epub ahead of print] PubMed PMID: 26871472.

    Dondossola E, Dobroff AS, Marchiò S, Cardó-Vila M, Hosoya H, Libutti SK, Corti A, Sidman RL, Arap W, Pasqualini R. Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors. Proc Natl Acad Sci U S A. 2016 Feb 8. pii: 201525697. [Epub ahead of print] PubMed PMID: 26858439.

    Fazio N, Buzzoni R, Baudin E, Antonuzzo L, Hubner RA, Lahner H, DE Herder WW, Raderer M, Teulé A, Capdevila J, Libutti SK, Kulke MH, Shah M, Dey D, Turri S, Aimone P, Massacesi C, Verslype C. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Res. 2016 Feb;36(2):713-9. PubMed PMID: 26851029.

    Serrano OK, Huang K, Ng N, Yang J, Friedmann P, Libutti SK, Kennedy TJ. Correlation between preoperative endoscopic ultrasound and surgical pathology staging of gastric adenocarcinoma: A single institution retrospective review. J Surg Oncol. 2016 Jan;113(1):42-5. doi: 10.1002/jso.24098. Epub 2016 Jan 19. PubMed PMID: 26784562.

    Assadipour Y, Azoury SC, Schaub NN, Hong Y, Eil R, Inchauste SM, Steinberg SM, Venkatesan AM, Libutti SK, Hughes MS. Significance of preoperative radiographic pancreatic density in predicting pancreatic fistula after surgery for pancreatic neuroendocrine tumors. Am J Surg. 2015 Dec 12. pii: S0002-9610(15)00659-5. doi: 10.1016/j.amjsurg.2015.07.031. [Epub ahead of print] PubMed PMID: 26782807.

    McKimpson WM, Yuan Z, Zheng M, Crabtree JS, Libutti SK, Kitsis RN. The Cell Death Inhibitor ARC Is Induced in a Tissue-Specific Manner by Deletion of the Tumor Suppressor Gene Men1, but Not Required for Tumor Development and Growth. PLoS One. 2015 Dec 28;10(12):e0145792. doi: 10.1371/journal.pone.0145792. eCollection 2015. PubMed PMID: 26709830.

    Libutti SK. Navigating the regulatory road to approval for cancer gene therapies. Cancer Gene Ther. 2015 Dec;22(12):553. doi: 10.1038/cgt.2015.62. PubMed PMID: 26658519.

    Laird AM, Libutti SK. Minimally Invasive Parathyroidectomy Versus Bilateral Neck Exploration for Primary Hyperparathyroidism. Surg Oncol Clin N Am. 2016 Jan;25(1):103-18. doi: 10.1016/j.soc.2015.08.012. Review. PubMed PMID: 26610777.

    Rosenberg AM, Friedmann P, Del Rivero J, Libutti SK, Laird AM. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors. Surgery. 2015 Nov 4. pii: S0039-6060(15)00840-5. doi: 10.1016/j.surg.2015.10.013. [Epub ahead of print] PubMed PMID: 26547726.

    Hong CW, Chow L, Turkbey EB, Lencioni R, Libutti SK, Wood BJ. Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors. Cardiovasc Intervent Radiol. 2015 Jul 31. [Epub ahead of print] PubMed PMID: 26228246.

    Shah M, Da Silva R, Gravekamp C, Libutti SK, Abraham T, Dadachova E. Targeted radionuclide therapies for pancreatic cancer. Cancer Gene Ther. 2015 Aug;22(8):375-9. doi: 10.1038/cgt.2015.32. Epub 2015 Jul 31. Review. PubMed PMID:26227823.

    Attarian S, Libutti SK, Chuy J. ACTH-Producing Pancreatic Neuroendocrine Tumor Presenting with Severe Hypokalemic Alkalosis: A Case Report. J Gastrointest Cancer. 2015 Jun 16. [Epub ahead of print] PubMed PMID: 26073616.

    Del Rivero J, Libutti SK. Invited commentary. Radiographics. 2015 Mar-Apr;35(2):516-8. doi: 10.1148/rg.352140286. PubMed PMID: 25763734.

    Libutti SK. Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy's smart bombs. Cancer Gene Ther. 2015 Mar;22(2):63. doi: 10.1038/cgt.2015.1. PubMed PMID: 25753044.

    Gabizon A, Bradbury M, Prabhakar U, Zamboni W, Libutti S, Grodzinski P. Cancer nanomedicines: closing the translational gap. Lancet. 2014 Dec 20;384(9961):2175-6. doi: 10.1016/S0140-6736(14)61457-4. Epub 2014 Dec 19. PubMed PMID: 25625382.

    Cui MH, Branch CA, Cahill SM, Quinn TJ, Adem A, Libutti SK, Yuan Z. In vivo proton MR spectroscopy of pancreatic neuroendocrine tumors in a multiple endocrine neoplasia type 1 conditional knockout mouse model. Magn Reson Med. 2014 Nov 13. doi: 10.1002/mrm.25529. [Epub ahead of print] PubMed PMID: 25392979.

    Kwon M, Libutti SK. Filamin A interacting protein 1-like as a therapeutic target in cancer. Expert Opin Ther Targets. 2014 Sep 9:1-13. [Epub ahead of print] PubMed PMID: 25200207.

    Debelenko LV, Agarwal S, Du Q, Yan W, Erickson HS, Abu-Asab M, Raffeld MA, Libutti SK, Marx SJ, Emmert-Buck MR. Menin Immunoreactivity in Secretory Granules of Human Pancreatic Islet Cells. Appl Immunohistochem Mol Morphol. 2014 Aug 22. [Epub ahead of print] PubMed PMID: 25153502.

    Vicente DA, Solomon NP, Avital I, Henry LR, Howard RS, Helou LB, Coppit GL, Shriver CD, Buckenmaier CC, Libutti SK, Shaha AR, Stojadinovic A. Voice Outcomes after Total Thyroidectomy, Partial Thyroidectomy, or Non-Neck Surgery Using a Prospective Multifactorial Assessment. J Am Coll Surg. 2014 Mar 18. pii: S1072-7515(14)00259-2. doi: 10.1016/j.jamcollsurg.2014.03.019. [Epub ahead of print] PubMed PMID: 24745621.

    Yuan Z, Opas EE, Vrikshajanani C, Libutti SK, Levine MA. Generation of mice encoding a conditional null allele of Gcm2. Transgenic Res. 2014 Apr 16. [Epub ahead of print] PubMed PMID: 24736975.

    Libutti SK. New horizons for cancer gene therapy. Cancer Gene Ther. 2014 Jan;21(1):1. doi: 10.1038/cgt.2013.80. PubMed PMID: 24492767.

    Cervera I, Boucai L, Andreopoulou P, Libutti SK, Hughes DT. Referral Patterns for Endocrine Surgical Disease. Endocr Pract. 2014 Jan 21:1-16. [Epub ahead of print] PubMed PMID: 24449658.

    Back to top 

    2012 - 2013 Publications

    Weisbrod AB, Kitano M, Thomas F, Williams D, Gulati N, Gesuwan K, Liu Y, Venzon D, Turkbey I, Choyke P, Yao J, Libutti SK, Nilubol N, Linehan WM, Kebebew E. Assessment of tumor growth in pancreatic neuroendocrine tumors in von hippel lindau syndrome. J Am Coll Surg. 2014 Feb;218(2):163-9. doi: 10.1016/j.jamcollsurg.2013.10.025. Epub 2013 Nov 12. PubMed PMID: 24440063.

    Kwon M, Lee SJ, Reddy S, Rybak Y, Adem A, Libutti SK. Down-Regulation of Filamin A interacting protein 1-like Is Associated with Promoter Methylation and an Invasive Phenotype in Breast, Colon, Lung and Pancreatic Cancers. PLoS One. 2013 Dec 5;8(12):e82620. doi: 10.1371/journal.pone.0082620. PubMed PMID: 24340050; PubMed Central PMCID: PMC3855469.

    Kwon M, Lee SJ, Wang Y, Rybak Y, Luna A, Reddy S, Adem A, Beaty BT, Condeelis JS, Libutti SK. Filamin A interacting protein 1-like inhibits WNT signaling and MMP expression to suppress cancer cell invasion and metastasis. Int J Cancer. 2013 Dec 10. doi: 10.1002/ijc.28662. [Epub ahead of print] PubMed PMID: 24327474.

    Libutti SK. Evolving paradigm for managing small nonfunctional incidentally discovered pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2013 Dec;98(12):4670-2. doi: 10.1210/jc.2013-3696. PubMed PMID: 24311793.

    Gluick T, Yuan Z, Libutti SK, Marx SJ. Mutation in CDKN2C (p18) and CDKN2D (p19) may cause sporadic parathyroid adenoma. Endocr Relat Cancer. 2013 Oct 14. [Epub ahead of print] PubMed PMID: 24127162.

    Scholl UI, Goh G, Stölting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW, Prasad ML, Hartung EA, Mauras N, Benson MR, Brady T, Shapiro JR, Loring E, Nelson-Williams C, Libutti SK, Mane S, Hellman P,  Westin G, Akerström G, Björklund P, Carling T, Fahlke C, Hidalgo P, Lifton RP. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013 Aug 4. doi: 10.1038/ng.2695. [Epub ahead of print] PubMed PMID: 23913001.

    Hong CW, Libutti SK, Wood BJ. Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma. Curr Oncol. 2013 Jun;20(3):e274-7. doi: 10.3747/co.20.1266. PubMed PMID: 23737698; PubMed Central PMCID: PMC3671035.

    Libutti SK. Therapy: Blockade of IGF-1R-not effective in neuroendocrine tumours. Nat Rev Endocrinol. 2013 Jun 4. doi: 10.1038/nrendo.2013.109. [Epub ahead of print] PubMed PMID: 23732282.

    Nilubol N, Weisbrod AB, Weinstein LS, Simonds WF, Jensen RT, Phan GQ, Hughes MS, Libutti SK, Marx S, Kebebew E. Utility of Intraoperative Parathyroid Hormone Monitoring in Patients with Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism Undergoing Initial Parathyroidectomy. World J Surg. 2013 May 31. [Epub ahead of print] PubMed PMID: 23722465.

    Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, Holtzman M, Hanna N, Turner K, Beresneva T, Zhu Y. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013 Mar 8. doi:pii: S0039-6060(13)00002-0. 10.1016/j.surg.2013.01.001. [Epub ahead of print] PubMed PMID: 23489943.

    Stevenson R, Libutti SK, Saif MW. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors. JOP. 2013 Mar 10;14(2):155-7. doi: 10.6092/1590-8577/1472. PubMed PMID: 23474561.

    Stevenson R, Libutti SK, Saif MW. Novel agents in gastroenteropancreatic neuroendocrine tumors. JOP. 2013 Mar 10;14(2):152-4. doi: 10.6092/1590-8577/1470. PubMed PMID: 23474560.

    Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol. 2013 Feb;20(2):555-61. doi: 10.1245/s10434-012-2651-5. Epub 2012 Dec 12. PubMed PMID: 23233234.

    Libutti SK, Inabnet WB 3rd. Force or stratagem? Surgery. 2012 Dec;152(6):975-6. doi: 10.1016/j.surg.2012.08.061. PubMed PMID: 23158171.

    Yuan Z, Syrkin G, Adem A, Geha R, Pastoriza J, Vrikshajanani C, Smith T, Quinn TJ, Alemu G, Cho H, Barrett JC, Arap W, Pasqualini R, Libutti SK. Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity. Cancer Gene Ther. 2012 Nov 16. doi: 10.1038/cgt.2012.83. [Epub ahead of print] PubMed PMID: 23154431.

    Turcotte S, Turkbey B, Barak S, Libutti SK, Alexander HR, Linehan WM, Hughes MS, Nilubol N, Gesuwan K, Millo C, Quezado M, Choyke PL, Kebebew E, Phan GQ. von Hippel-Lindau disease-associated solid microcystic serous adenomas masquerading as pancreatic neuroendocrine neoplasms. Surgery. 2012 Oct 26. doi:pii: S0039-6060(12)00454-0. 10.1016/j.surg.2012.08.010. [Epub ahead of print] PubMed PMID: 23107912.

    Quinn TJ, Yuan Z, Adem A, Geha R, Vrikshajanani C, Koba W, Fine E, Hughes DT, Schmid H, Libutti SK. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1(MEN1) conditional knockout mouse model. Surgery. 2012 Oct 24. pii:S0039-6060(12)00474-6. doi:10.1016/j.surg.2012.08.021. [Epub ahead of print]PubMed PMID: 23102680.

    Weisbrod AB, Nilubol N, Weinstein LS, Simonds WF, Libutti SK, Jensen RT, Marx SJ, Kebebew E. Association of Type-O Blood with Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. J Clin Endocrinol Metab. 2012 Oct 23. [Epub ahead of print] PubMed PMID: 23093487.

    Neary NM, El-Maouche D, Hopkins R, Libutti SK, Moses AM, Weinstein LS. Development and Treatment of Tertiary Hyperparathyroidism in Patients with Pseudohypoparathyroidism Type 1B. J Clin Endocrinol Metab. 2012 Jun 26. [Epub ahead of print] PubMed PMID: 22736772.

    Henry L, Helou L, Solomon N, Chang A, Libutti S, Stojadinovic A. Current Practice Patterns Regarding the Conduct of Thyroidectomy and Parathyroidectomy amongst Surgeons - A Survey Study. J Cancer. 2012;3:207-16. Epub 2012 May 12. PubMed PMID: 22606210; PubMed Central PMCID: PMC3354416.

    Inchauste SM, Lanier BJ, Libutti SK, Phan GQ, Nilubol N, Steinberg SM, Kebebew E, Hughes MS. Rate of Clinically Significant Postoperative Pancreatic Fistula in Pancreatic Neuroendocrine Tumors. World J Surg. 2012 Apr 24. [Epub ahead of print] PubMed PMID: 22526042.

    Yavuz S, Simonds WF, Weinstein LS, Collins MT, Kebebew E, Nilubol N, Phan GQ, Libutti SK, Remaley AT, Van Deventer M, Marx SJ. Sleeping Parathyroid Tumor: Rapid Hyperfunction after Removal of the Dominant Tumor. J Clin Endocrinol Metab. 2012 Apr 16. [Epub ahead of print] PubMed PMID: 22508712.

    Oberstein PE, Remotti H, Saif MW, Libutti SK. Pancreatic neuroendocrine tumors: entering a new era. JOP. 2012 Mar 10;13(2):169-73. PubMed PMID: 22406593.

    Weisbrod AB, Liewehr DJ, Steinberg SM, Patterson EE, Libutti SK, Marston Linehan W, Nilubol N, Kebebew E. Association of Type O Blood with Pancreatic Neuroendocrine Tumors in Von Hippel-Lindau Syndrome. Ann Surg Oncol. 2012 Feb 16. [Epub ahead of print] PubMed PMID: 22350603.

    Nilubol N, Weinstein L, Simonds WF, Jensen RT, Phan GQ, Hughes MS, Libutti SK, Marx S, Kebebew E. Preoperative Localizing Studies for Initial Parathyroidectomy in MEN1 Syndrome: Is There Any Benefit? World J Surg. 2012 Feb 15. [Epub ahead of print] PubMed PMID: 22350475.

    Arciero CA, Shiue ZS, Gates JD, Peoples GE, Dackiw AP, Tufano RP, Libutti SK, Zeiger MA, Stojadinovic A. Preoperative thyroid ultrasound is indicated in patients undergoing parathyroidectomy for primary hyperparathyroidism. J Cancer. 2012;3:1-6. Epub 2011 Nov 25. PubMed PMID: 22211139; PubMed Central PMCID: PMC3245602.

    Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK,  Fojo T, Schrump DS, Avital I. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol. 2011 Dec 20. doi: 10.1002/jso.23015. [Epub ahead of print] PubMed PMID: 22189845.

    Wood BJ, Poon RT, Locklin JK, Dreher MR, Ng KK, Eugeni M, Seidel G, Dromi S, Neeman Z, Kolf M, Black CD, Prabhakar R, Libutti SK. Phase I Study of Heat-Deployed Liposomal Doxorubicin during Radiofrequency Ablation for Hepatic Malignancies. J Vasc Interv Radiol. 2012 Feb;23(2):248-255.e7. Epub 2011 Dec 16. PubMed PMID: 22178041; PubMed Central PMCID: PMC3264789.

    Back to top 

    2010 - 2011 Publications

    Prasad N, Kowalski J, Tsai HL, Talbot K, Somervell H, Kouniavsky G, Wang Y, Dackiw A, Westra WH, Clark DP, Libutti SK, Umbricht CB, Zeiger MA. Three-Gene Molecular Diagnostic Model for Thyroid Cancer. Thyroid. 2011 Dec 9. [Epub ahead of print] PubMed PMID: 22150595.

    Kitano M, Millo C, Rahbari R, Herscovitch P, Gesuwan K, Webb RC, Venkatesan AM, Phan GQ, Hughes MS, Libutti SK, Nilubol N, Linehan WM, Kebebew E. Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. Surgery. 2011 Dec;150(6):1122-8. PubMed PMID: 22136831.

    Webb R, Mathur A, Chang R, Baid S, Nilubol N, Libutti SK, Stratakis CA, Kebebew E. What is the Best Criterion for the Interpretation of Adrenal Vein Sample Results in Patients with Primary Hyperaldosteronism? Ann Surg Oncol. 2011 Nov 3. [Epub ahead of print] PubMed PMID: 22048631.

    Burton ER, Gaffar A, Lee SJ, Adeshuko F, Whitney KD, Chung JY, Hewitt SM, Huang GS, Goldberg GL, Libutti SK, Kwon M. Down-regulation of filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer. Mol Cancer Res. 2011 Jun 21. [Epub ahead of print] PubMed PMID: 21693594.

    Spiegel AM, Libutti SK. Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors. Nat Rev Clin Oncol. 2011 Mar 29. [Epub ahead of print] PubMed PMID: 21448150.

    Citrin D, Camphausen K, Wood BJ, Quezado M, Denobile J, Pingpank JF, Royal RE, Alexander HR, Seidel G, Steinberg SM, Shuttack Y, Libutti SK. A Pilot Feasibility Study of TNFerade™ Biologic with Capecitabine and Radiation Therapy Followed by Surgical Resection for the Treatment of Rectal Cancer. Oncology. 2011 Mar 25;79(5-6):382-388. [Epub ahead of print] PubMed PMID: 21447969.

    Rosen JE, Libutti SK, Lee SL. Thyroid Cancer: Molecular and Modern Advances. J Oncol. 2010;2010:317034. Epub 2011 Feb 7. PubMed PMID: 21331370.

    Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK, Steinberg SM, Wood BJ, Kammula US, Fojo T, Avital I. Liver Resection and Ablation for Metastatic Adrenocortical Carcinoma. Ann Surg Oncol. 2011 Feb 8. [Epub ahead of print] PubMed PMID: 21301973.

    Spiegel AM, Libutti SK. Future diagnostic and therapeutic trends in endocrine cancers. Semin Oncol. 2010 Dec;37(6):691-5. Review. PubMed PMID: 21167386.

    Libutti SK. Endocrine surgery specialty training: Opportunities for growth. Surgery. 2010 Dec;148(6):1073-4. PubMed PMID: 21134535.

    Libutti SK, Paciotti GF, Byrnes AA, Alexander HR, Gannon WE Jr, Walker M, Seidel GD, Yuldasheva N, Tamarkin L. Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine. Clin Cancer Res. 2010 Sep 27. [Epub ahead of print] PubMed PMID: 20876255.

    Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, Steinberg SM, Wunderlich J, Alexander HR Jr. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer. 2010 Sep 13. [Epub ahead of print] PubMed PMID: 20839315.

    Sreeramoju P, Libutti SK. Strategies for targeting tumors and tumor vasculature for cancer therapy. Adv Genet. 2010;69:135-52. PubMed PMID: 20807606.

    Mathur A, Kemp CD, Dutta U, Baid S, Ayala A, Chang RE, Steinberg SM, Papademetriou V, Lange E, Libutti SK, Pingpank JF, Alexander HR, Phan GQ, Hughes M, Linehan WM, Pinto PA, Stratakis CA, Kebebew E. Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg. 2010 Sep;211(3):384-90. Epub 2010 Jul 14. PubMed PMID: 20800196; PubMed Central PMCID: PMC2930893.

    Alsamarai S, Libutti SK, Saif MW. Updates in pancreatic neuroendocrine carcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP. 2010 Jul 5;11(4):336-40. PubMed PMID: 20601807.

    Shen HC, Ylaya K, Pechhold K, Wilson A, Adem A, Hewitt SM, Libutti SK. Multiple Endocrine Neoplasia Type 1 Deletion in Pancreatic {alpha}-Cells Leads to Development of Insulinomas in Mice. Endocrinology. 2010 Jun 16. [Epub ahead of print] PubMed PMID: 20555035.

    Powell AC, Paciotti GF, Libutti SK. Colloidal gold: a novel nanoparticle for targeted cancer therapeutics. Methods Mol Biol. 2010;624:375-84. PubMed PMID: 20217609.

    Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010 Feb;6(2):229-37. PubMed PMID: 20146582.

    Back to top

     

     

    precision medicine at Rutgers Cancer Institute

     

     

     

    Donate Now

     

     

     


     

     

     

     

    Proud member of
    Big Ten Cancer Research Consortium

     

     

    Rutgers Health